[143817657]
This case is follow-up to usade reports originally submitted in 2014 (manufacture report number: 3002124545-2014-00012). 2 therasphere? Vials were used to treat this patient, it cannot be determined which device contributed to this fatal event. Refer to mdr 3002124543-2019-00032 for the other device associated with this event. (b)(4). Subject: (b)(6). Last sae report: 15 apr 2019. Sae: rild (radio-embolization induced liver disease) (radiation hepatitis). This report concerns subject (b)(6), a female subject who was born in (b)(6) enrolled in study (b)(6) entitled "(b)(6)". On (b)(6) 2014, the subject received first cycle of second-line chemotherapy, folfiri regimen (irinotecan, folinic acid and fluorouracil). On (b)(6) 2014, the subject received treatment with total 2 vials of therasphere?. The right hepatic lobe was treated at a dose of 118 gy (lot no 4990036/18, expiry date: 07 mar 2014) and at a dose of 136 gy in the left hepatic lobe (lot no 4990031, expiry date: 07 mar 2014). On (b)(6) 2014, the subject received most recent cycle (fifth) prior to the event of second-line chemotherapy, folfiri regimen (irinotecan 295. 2 mg intravenous (iv), folinic acid 35 mg iv and fluorouracil 656 mg iv and 3936 mg iv bolus) which completed on (b)(6) 2014. There are no relevant medical history to the event. Concomitant medications include bisoprolol, macrogol, calcium, lorazepam, ispaghul, ondansetron, methylprednisolone, atropine, aprepitant, alprazolam, clinutren, prednisolone, lactulose, amoxicillin and rocephin. On (b)(6) 2014, approximately three months after receiving treatment with the study device and initiating chemotherapy, the subject was admitted to the hospital with asthenia, pleural effusion, ascites, cholestasis, decreased prothrombin time and increased bilirubin (values unknown). On (b)(6) 2014, a ct (computed tomography) scan was performed which showed disappeared liver metastases with very heterogeneous liver structure, splenomegaly and presence of non-vascularized thrombosis of portal vein in both right and left branch up to the mesenteric vein at ctcae grade 3. The investigator diagnosed the events as rild (radio-embolization induced liver disease), portal vein thrombosis and mesenteric vein thrombosis. Pleural effusion, ascites, cholestasis and increased bilirubin were considered as the consequence of rild. On (b)(6) 2014, the subject died due to the event of rild (radio-embolization induced liver disease). The subject discontinued participation in the study due to her death. The investigator assessed the event of rild (radio-embolization induced liver disease) as grade-5 (fatal) in intensity, serious due to hospitalization and death; and definitely related to the study device; not related to the study procedure and second line chemotherapy (folfiri regimen). The event was considered to be related to disease under study (clinical progression not confirmed via ct). The company agreed with the investigator's assessment. No additional information is expected at this time.
Patient Sequence No: 1, Text Type: D, B5